Sutro Biopharma (STRO) News Today $0.90 -0.01 (-0.91%) Closing price 04:00 PM EasternExtended Trading$0.90 +0.00 (+0.29%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock STRO Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Affinity Asset Advisors LLC Makes New Investment in Sutro Biopharma, Inc. $STROAugust 28 at 9:09 AM | marketbeat.comWall Street Zen Downgrades Sutro Biopharma (NASDAQ:STRO) to SellAugust 25 at 2:44 AM | marketbeat.comSutro Biopharma (NASDAQ:STRO) Rating Lowered to Sell at Wall Street ZenAugust 24, 2025 | americanbankingnews.comSutro Biopharma’s STRO-002: A Promising Phase 1 Trial Update in Ovarian and Endometrial CancersAugust 20, 2025 | msn.comSutro Biopharma (STRO) Gets a Buy from Truist FinancialAugust 14, 2025 | theglobeandmail.comWells Fargo & Company Cuts Sutro Biopharma (NASDAQ:STRO) Price Target to $3.00August 13, 2025 | marketbeat.comSutro Biopharma price target lowered to $3 from $4 at Wells FargoAugust 12, 2025 | msn.comSutro Biopharma (NASDAQ:STRO) Upgraded at Wall Street ZenAugust 10, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO) and Relay Therapeutics (RLAY)August 9, 2025 | theglobeandmail.comSutro Biopharma, Inc.: Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business HighlightsAugust 8, 2025 | finanznachrichten.deSutro Biopharma Reports Second Quarter 2025 Financial Results and Business HighlightsAugust 7, 2025 | globenewswire.comSutro Biopharma (STRO) Expected to Announce Quarterly Earnings on TuesdayAugust 6, 2025 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Hold" from AnalystsAugust 5, 2025 | marketbeat.comSutro Biopharma (NASDAQ:STRO) Trading 0.6% Higher - Time to Buy?August 3, 2025 | marketbeat.comSutro Biopharma, Inc.: Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug ConjugatesJuly 24, 2025 | finanznachrichten.deHere's Why Sutro Biopharma (NASDAQ:STRO) Must Use Its Cash WiselyJuly 23, 2025 | finance.yahoo.comSutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug ConjugatesJuly 23, 2025 | finance.yahoo.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Recommendation of "Hold" from BrokeragesJuly 11, 2025 | marketbeat.comSutro Biopharma (NASDAQ:STRO) Upgraded by Piper Sandler to Overweight RatingJune 16, 2025 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of "Hold" by AnalystsJune 16, 2025 | marketbeat.comSutro Biopharma upgraded to Overweight from Neutral at Piper SandlerJune 16, 2025 | msn.comSutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Millennium Management LLCJune 7, 2025 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Short Interest UpdateJune 3, 2025 | marketbeat.comSutro Biopharma Appoints Greg Chow as Chief Financial OfficerJune 2, 2025 | finance.yahoo.comSutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of "Hold" by BrokeragesMay 24, 2025 | marketbeat.comPoint72 Asset Management L.P. Has $4.04 Million Stock Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO)May 22, 2025 | marketbeat.com2,570,000 Shares in Sutro Biopharma, Inc. (NASDAQ:STRO) Purchased by Vestal Point Capital LPMay 21, 2025 | marketbeat.comSuvretta Capital Management LLC Grows Position in Sutro Biopharma, Inc. (NASDAQ:STRO)May 19, 2025 | marketbeat.comMPM Bioimpact LLC Has $3.98 Million Position in Sutro Biopharma, Inc. (NASDAQ:STRO)May 16, 2025 | marketbeat.comSutro Biopharma (NASDAQ:STRO) Releases Earnings Results, Misses Expectations By $0.28 EPSMay 14, 2025 | marketbeat.comSutro Biopharma, Inc.: Sutro Biopharma Reports First Quarter 2025 Financial Results and Business HighlightsMay 9, 2025 | finanznachrichten.deSutro Biopharma Reports First Quarter 2025 Financial Results and Business HighlightsMay 8, 2025 | globenewswire.comSutro Biopharma (STRO) Expected to Announce Quarterly Earnings on MondayMay 7, 2025 | marketbeat.comSutro Biopharma to Participate in Upcoming Investor ConferencesMay 1, 2025 | globenewswire.comSutro Biopharma (NASDAQ:STRO) Given Neutral Rating at HC WainwrightMay 1, 2025 | marketbeat.comHC Wainwright Lifts Earnings Estimates for Sutro BiopharmaMarch 20, 2025 | marketbeat.comSutro Biopharma downgraded to Neutral from Buy at H.C. WainwrightMarch 17, 2025 | markets.businessinsider.comHC Wainwright & Co. Downgrades Sutro Biopharma (STRO)March 17, 2025 | msn.comSutro Biopharma presents expanded data from REFRalphaME-01 trialMarch 16, 2025 | markets.businessinsider.comSutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025March 15, 2025 | tmcnet.comSutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025March 15, 2025 | tmcnet.comSutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025March 15, 2025 | globenewswire.comWedbush Downgrades Sutro Biopharma (STRO)March 15, 2025 | msn.comSutro Biopharma (NASDAQ:STRO) Downgraded to Market Perform Rating by Citizens JmpMarch 15, 2025 | marketbeat.comWedbush Downgrades Sutro Biopharma (NASDAQ:STRO) to NeutralMarch 15, 2025 | marketbeat.comSutro Biopharma (NASDAQ:STRO) Lowered to "Underperform" Rating by Bank of AmericaMarch 15, 2025 | marketbeat.comSutro Biopharma (NASDAQ:STRO) Announces Earnings ResultsMarch 14, 2025 | marketbeat.comSutro Biopharma downgraded to Neutral from Overweight at Piper SandlerMarch 14, 2025 | markets.businessinsider.comSutro drops as portfolio review leads to downgradesMarch 14, 2025 | msn.comSutro Biopharma, Inc.: Sutro Biopharma Reports Full Year 2024 Financial Results and Business HighlightsMarch 14, 2025 | finanznachrichten.de Get Sutro Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STRO Media Mentions By Week STRO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. STRO News Sentiment▼0.701.02▲Average Medical News Sentiment STRO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. STRO Articles This Week▼42▲STRO Articles Average Week Get the Latest News and Ratings for STRO and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Sutro Biopharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Atea Pharmaceuticals News Neurogene News Lifecore Biomedical News Aurora Cannabis News Contineum Therapeutics News Vor Biopharma News DBV Technologies News Mereo BioPharma Group News Jade Biosciences News Lexeo Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:STRO) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sutro Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access